According to the results, treatment with inflammasome inhibitors appeared to inhibit the proliferation of breast cancer cells in estrogen receptor-positive breast cancer cells (MCF7 and T47D), but this effect was not observed in triple-negative breast cancer cells (MDAMB231). This evidence concerns the gene ESR1 and breast carcinoma.